The EPS miss and maintained lowered guidance reinforce the bearish narrative from the prior quarter's guidance cut. Monitor the Q3 FY2027 earnings for signs of stabilization in network solutions revenue and the pace of restructuring savings realization. The stock has historically underperformed post-earnings, with a 22% win rate at T+20 on prior reports.
Price Chart
Executive Summary
Phreesia reported Q2 FY2027 revenue of $129.5M (+10% YoY), in line with consensus, but GAAP EPS of $0.03 was a significant miss vs the $0.10 Street consensus. The company maintained its lowered FY2027 revenue guidance of $510-520M and EBITDA guidance of $125-135M, citing ongoing variability in network solutions revenue from pharma budget pullbacks. A restructuring plan eliminating ~220 positions was implemented in May 2026, with $2.8M in charges recognized this quarter. The stock faces headwinds from the EPS miss, guided revenue deceleration, and a history of poor post-earnings performance.
Key Financial Metrics
Key Facts
- Total revenue of $129.5M, up 10% YoY, in line with consensus of $129.0M
- GAAP diluted EPS of $0.03, missing Street consensus of $0.10 by ~70%
- Subscription revenue declined 2% YoY to $52.7M; payment solutions grew 36% to $38.5M; network solutions grew 9% to $38.3M
- FY2027 revenue guidance maintained at $510-520M (implying ~flat to -3% YoY at midpoint), lowered from prior $545-559M in March 2026
- Adjusted EBITDA of $32.9M, up 49% YoY; FY2027 EBITDA guidance maintained at $125-135M
- Restructuring plan announced May 7, 2026: ~220 positions eliminated, ~$10M total charges expected; $2.8M recognized in Q2
- Debt reduced by $23.5M during Q2; $60.7M outstanding on $275M Capital One credit facility as of July 31, 2026
- Free cash flow of $13.8M, up from $9.6M in prior year quarter
- Historical performance shows 22% win rate at T+20 on prior PHR reports, with average T+20 return of -10.81%
Financial Impact
GAAP EPS of $0.03 vs $0.10 consensus (-70% miss); revenue in line at $129.5M; FY2027 revenue guidance cut to $510-520M from $545-559M (midpoint -6.5%)
Risk Factors
- Network solutions revenue variability from pharma budget pullbacks (vaccines, GLP-1, public health) may persist or worsen
- Subscription revenue decline (-2% YoY) signals potential client churn or pricing pressure
- Restructuring execution risk: ~220 positions eliminated may disrupt operations or client relationships
- Elevated debt ($60.7M) and interest expense ($1.7M in Q2) limit financial flexibility
- Historical post-earnings drift on PHR has been negative, with average T+20 return of -10.81% across 9 prior reports
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001412408-26-000213 |
| Document: phr-ex992q2fy27stakehold.htm | 0001412408-26-000213 |
| Document: phr-20260902.htm | 0001412408-26-000213 |
| Document: 0001412408-26-000213-index-headers.html | 0001412408-26-000213 |
| Document: 0001412408-26-000213-index.html | 0001412408-26-000213 |
| Document: 0001412408-26-000213.txt | 0001412408-26-000213 |
| 8-K Data (Synthetic) | 0001412408-26-000213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $11.10 $10.07 | ▲ +9.28% | ▲ +8.09% | $10.36 (+6.67%) |
May 14, 2026 20w ago | DEFA14A | $8.77 $9.15 | ▲ +4.33% | ▲ +2.21% | $10.36 (+18.13%) |
Apr 10, 2026 25w ago | Insider Cluster | $8.06 $9.83 | ▼ −21.96% | ▼ −13.43% | $10.36 (−28.54%) |
Apr 10, 2026 25w ago | Insider Cluster | $8.06 $9.83 | ▼ −21.96% | ▼ −13.43% | $10.36 (−28.54%) |
Apr 3, 2026 26w ago | 8-K | $9.15 $9.67 | ▼ −5.68% | ▲ +3.30% | $10.36 (−13.22%) |
Mar 18, 2026 28w ago | Insider Cluster | $11.20 $9.17 | ▼ −18.13% | ▼ −24.17% | $10.36 (−7.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access